Journal Article
. 2016 Dec; 11(12):e0168730.
doi: 10.1371/journal.pone.0168730.

Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study

Joachim Diessner 1 Manfred Wischnewsky 2 Maria Blettner 3 Sebastian Häusler 1 Wolfgang Janni 4 Rolf Kreienberg 4 Roland Stein 1 Tanja Stüber 1 Lukas Schwentner 4 Catharina Bartmann 1 Achim Wöckel 1 
Affiliations
  • PMID: 27992550
  •     39 References
  •     6 citations

Abstract

Background: Luminal A breast cancers respond well to anti-hormonal therapy (HT), are associated with a generally favorable prognosis and constitute the majority of breast cancer subtypes. HT is the mainstay of treatment of these patients, accompanied by an acceptable profile of side effects, whereas the added benefit of chemotherapy (CHT), including anthracycline and taxane-based programs, is less clear-cut and has undergone a process of critical revision.

Methods: In the framework of the BRENDA collective, we analyzed the benefits of CHT compared to HT in 4570 luminal A patients (pts) with primary diagnosis between 2001 and 2008. The results were adjusted by nodal status, age, tumor size and grading.

Results: There has been a progressive reduction in the use of CHT in luminal A patients during the last decade. Neither univariate nor multivariate analyses showed any statistically significant differences in relapse free survival (RFS) with the addition of CHT to adjuvant HT, independent of the nodal status, age, tumor size or grading. Even for patients with more than 3 affected lymph nodes, there was no significant difference (univariate: p = 0.865; HR 0.94; 95% CI: 0.46-1.93; multivariate: p = 0.812; HR 0.92; 95% CI: 0.45-1.88).

Conclusions: The addition of CHT to HT provides minimal or no clinical benefit at all to patients with luminal A breast cancer, independent of the RFS-risk. Consequently, risk estimation cannot be the initial step in the decisional process. These findings-that are in line with several publications-should encourage the critical evaluation of applying adjuvant CHT to patients with luminal A breast cancer.

Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.
Joachim Diessner, Manfred Wischnewsky, +9 authors, Catharina Bartmann.
BMC Cancer, 2016 May 14; 16. PMID: 27175930    Free PMC article.
Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer.
Bent Ejlertsen, Henning T Mouridsen, +5 authors, Danish Breast Cancer Cooperative Group.
Cancer, 2010 Feb 27; 116(9). PMID: 20186830
The National Institutes of Health Consensus Development Conference: Adjuvant Therapy for Breast Cancer. Bethesda, Maryland, USA. November 1-3, 2000. Proceedings.
J Natl Cancer Inst Monogr, 2002 Jun 27; (30). PMID: 12083020
Review.
Criteria for prediction of metastatic axillary lymph nodes in early-stage breast cancer.
Helio Rubens de Oliveira Filho, Maíra Teixeira Dória, +4 authors, Marcos Desidério Ricci.
Rev Bras Ginecol Obstet, 2015 Aug 08; 37(7). PMID: 26247250
Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG).
J Natl Cancer Inst, 2002 Jul 18; 94(14). PMID: 12122096
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
Donald A Berry, Constance Cirrincione, +9 authors, Eric P Winer.
JAMA, 2006 Apr 13; 295(14). PMID: 16609087    Free PMC article.
Highly Cited.
Postmenopausal breast cancer: a best endocrine strategy?
Erica L Mayer, Harold J Burstein.
Lancet, 2015 Jul 28; 386(10001). PMID: 26211823
Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response.
E H Lips, L Mulder, +5 authors, J Wesseling.
Breast Cancer Res Treat, 2013 Jul 06; 140(1). PMID: 23828499    Free PMC article.
The association between biological subtype and isolated regional nodal failure after breast-conserving therapy.
Jennifer Y Wo, Alphonse G Taghian, +7 authors, Jay R Harris.
Int J Radiat Oncol Biol Phys, 2010 Feb 23; 77(1). PMID: 20171798
Molecular portraits of human breast tumours.
C M Perou, T Sørlie, +15 authors, D Botstein.
Nature, 2000 Aug 30; 406(6797). PMID: 10963602
Highly Cited.
ABC3 Consensus: Assessment by a German Group of Experts.
Christoph Thomssen, Doris Augustin, +12 authors, Nadia Harbeck.
Breast Care (Basel), 2016 Apr 07; 11(1). PMID: 27051399    Free PMC article.
Adjuvant chemotherapy in luminal breast cancers.
Elgene Lim, Eric P Winer.
Breast, 2011 Nov 02; 20 Suppl 3. PMID: 22015279
Review.
The role of molecular analysis in breast cancer.
Felipe C Geyer, Caterina Marchio, Jorge S Reis-Filho.
Pathology, 2008 Dec 18; 41(1). PMID: 19089743
Review.
Adjuvant chemotherapy may improve survival of patients with luminal A breast cancer and positive lymph nodes.
Y Han, Q Li, +6 authors, Y Fan.
Genet Mol Res, 2015 Sep 09; 14(3). PMID: 26345787
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Giuseppe Viale, Meredith M Regan, +16 authors, Alan S Coates.
J Clin Oncol, 2008 Mar 20; 26(9). PMID: 18349391
Repeated observation of breast tumor subtypes in independent gene expression data sets.
Therese Sorlie, Robert Tibshirani, +13 authors, David Botstein.
Proc Natl Acad Sci U S A, 2003 Jun 28; 100(14). PMID: 12829800    Free PMC article.
Highly Cited.
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
A Goldhirsch, W C Wood, +4 authors, Panel members.
Ann Oncol, 2011 Jun 29; 22(8). PMID: 21709140    Free PMC article.
Highly Cited.
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.
Torsten O Nielsen, Joel S Parker, +12 authors, Matthew J Ellis.
Clin Cancer Res, 2010 Sep 15; 16(21). PMID: 20837693    Free PMC article.
Highly Cited.
High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial.
Torsten O Nielsen, Maj-Brit Jensen, +4 authors, Bent Ejlertsen.
Clin Cancer Res, 2016 Sep 08; 23(4). PMID: 27601592
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
A Howell, J Cuzick, +8 authors, ATAC Trialists' Group.
Lancet, 2005 Jan 11; 365(9453). PMID: 15639680
Highly Cited.
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, +10 authors, Lajos Pusztai.
J Clin Oncol, 2008 Feb 06; 26(8). PMID: 18250347
Highly Cited.
Is adjuvant chemotherapy useful for women with luminal a breast cancer?
Alan S Coates, Marco Colleoni, Aron Goldhirsch.
J Clin Oncol, 2012 Feb 23; 30(12). PMID: 22355052
Review.
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.
Kathy S Albain, William E Barlow, +18 authors, Breast Cancer Intergroup of North America.
Lancet, 2009 Dec 17; 374(9707). PMID: 20004966    Free PMC article.
Identifying the impact of inflammatory breast cancer on survival: a retrospective multi-center cohort study.
J Diessner, R Van Ewijk, +7 authors, L Schwentner.
Arch Gynecol Obstet, 2015 Mar 31; 292(3). PMID: 25814296
Changes over time in the impact of gene-expression profiles on the administration of adjuvant chemotherapy in estrogen receptor positive early stage breast cancer patients: A nationwide study.
A Kuijer, C A Drukker, +4 authors, Th van Dalen.
Int J Cancer, 2016 Apr 12; 139(4). PMID: 27062369
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.
Judith Hugh, John Hanson, +11 authors, Charles Vogel.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204205    Free PMC article.
Highly Cited.
Reproductive history and risk of three breast cancer subtypes defined by three biomarkers.
Amanda I Phipps, Diana S M Buist, +4 authors, Christopher I Li.
Cancer Causes Control, 2010 Dec 25; 22(3). PMID: 21184265    Free PMC article.
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Gunter von Minckwitz, Michael Untch, +14 authors, Sibylle Loibl.
J Clin Oncol, 2012 Apr 18; 30(15). PMID: 22508812
Highly Cited.
Adjuvant endocrine therapy for postmenopausal women: Type and duration.
Erica L Mayer, Harold J Burstein.
Breast, 2015 Aug 19; 24 Suppl 2. PMID: 26279133
Effect of chemotherapy for luminal a breast cancer.
Naotaka Uchida, Takako Suda, Kiyosuke Ishiguro.
Yonago Acta Med, 2013 Sep 14; 56(2). PMID: 24031152    Free PMC article.
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
Paul L Nguyen, Alphonse G Taghian, +7 authors, Jay R Harris.
J Clin Oncol, 2008 Apr 17; 26(14). PMID: 18413639
Highly Cited.
Epidemiology of basal-like breast cancer.
Robert C Millikan, Beth Newman, +13 authors, Charles M Perou.
Breast Cancer Res Treat, 2007 Jun 21; 109(1). PMID: 17578664    Free PMC article.
Highly Cited.
Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers.
Carol A Parise, Vincent Caggiano.
J Cancer Epidemiol, 2014 Jun 24; 2014. PMID: 24955090    Free PMC article.
Highly Cited.
Is adjuvant chemotherapy omissible in women with T1-2 stage, node-positive, luminal A type breast cancer?
Hee Yong Kwak, Byung Joo Chae, +5 authors, Byung Joo Song.
J Chemother, 2015 May 15; 27(5). PMID: 25974160
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients.
Volker Möbus.
Breast Care (Basel), 2016 Apr 07; 11(1). PMID: 27051389    Free PMC article.
Review.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, +14 authors, A L Børresen-Dale.
Proc Natl Acad Sci U S A, 2001 Sep 13; 98(19). PMID: 11553815    Free PMC article.
Highly Cited.
Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer.
P Karlsson, Z Sun, +14 authors, A Goldhirsch.
Ann Oncol, 2011 Feb 18; 22(10). PMID: 21325445    Free PMC article.
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.
S Aebi, Z Sun, +14 authors, A Goldhirsch.
Ann Oncol, 2011 Feb 02; 22(9). PMID: 21282282    Free PMC article.
Epigenetic Mechanisms of Tamoxifen Resistance in Luminal Breast Cancer.
Hany A Abdel-Hafiz.
Diseases, 2017 Sep 22; 5(3). PMID: 28933369    Free PMC article.
Review.
The Notch Pathway in Breast Cancer Progression.
Emmanuel N Kontomanolis, Sofia Kalagasidou, +4 authors, Zacharias N Fasoulakis.
ScientificWorldJournal, 2018 Aug 17; 2018. PMID: 30111989    Free PMC article.
Review.
Guideline-concordant chemotherapy in patients with hormone receptor-positive and node-positive, early breast cancer leads to better overall and metastases-free survival with limited benefit in elderly patients.
Clara Taubenhansl, Olaf Ortmann, +2 authors, Monika Klinkhammer-Schalke.
Arch Gynecol Obstet, 2019 Nov 22; 301(2). PMID: 31749031    Free PMC article.
Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study.
Daniel Herr, Manfred Wischnewsky, +10 authors, Achim Wöckel.
PLoS One, 2019 Jul 10; 14(7). PMID: 31283775    Free PMC article.
Evaluation of efficacy of chemotherapy for mucinous carcinoma: a surveillance, epidemiology, and end results cohort study.
Hanwen Zhang, Ning Zhang, +2 authors, Qifeng Yang.
Ther Adv Med Oncol, 2021 Jan 12; 12. PMID: 33425023    Free PMC article.
Establishment and Validation of Novel Clinical Prognosis Nomograms for Luminal A Breast Cancer Patients with Bone Metastasis.
QiHao Tu, Chuan Hu, +9 authors, XueXiao Ma.
Biomed Res Int, 2021 Jan 26; 2020. PMID: 33490234    Free PMC article.